Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
On its third quarter of 2026 earnings call, held on Oct. 13, 2026, Johnson & Johnson (NYSE:JNJ) raised its full-year sales outlook after operational revenue grew 6%. Strong pharmaceutical demand helped the healthcare giant absorb legal costs and medical device headwinds outside the U.S. Three takeaways from the call stand out for long-term investors. The company's Innovative Medicine division, which develops prescription drugs, powered performance with 7.9% operational growth. Cancer treatments led the gains, while Tremfya, an injectable therapy for inflammatory diseases, expanded its market share. This momentum keeps the company on pace to breach a historic sales threshold this year. Operational growth in MedTech, the company's medical device segment, slowed to 2.5% due to disruptions in the Middle East, volume-based procurement, a government bulk-buying program in China, and delays in the adoption of Abiomed heart pumps. Management plans to restore double-digit growth through new product rollouts, including OTTAVA, its soft-tissue robotic surgery system. Continue reading